Inhibitors of the rock serine/threonine kinases: Key effectors of the rhoa small GTPase.

Enzymes

Volumn 33, Issue , 2013, Pages 193-212

  Vigil, Dominico ^a   Der, Channing J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cofilin; Effector; Myosin light chain; RhoA

Indexed keywords

COFILIN; EFFECTOR; ENZYME INHIBITOR; MYOSIN LIGHT CHAIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL; ARTICLE; DRUG ANTAGONISM; HUMAN; METABOLISM; RHOA;

COFILIN; EFFECTOR; MYOSIN LIGHT CHAIN; RHOA;

ANIMALS; ENZYME INHIBITORS; HUMANS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN;

EID: 84881492297     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416749-0.00009-9     Document Type: Chapter

References (76)

1. Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A., Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S. The small GTP-binding protein Rho binds to and activates a 160kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996, 15(8):1885-1893.
2. Ishizaki T., Naito M., Fujisawa K., Maekawa M., Watanabe N., Saito Y., Narumiya S. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 1997, 404(2-3):118-124.
3. Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., Yamamori B., Feng J., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273(5272):245-248.
4. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 1996, 271(34):20246-20249.
5. Ito M., Nakano T., Erdodi F., Hartshorne D.J. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 2004, 259(1-2):197-209.
6. Totsukawa G., Yamakita Y., Yamashiro S., Hartshorne D.J., Sasaki Y., Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 2000, 150(4):797-806.
7. Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A., Obinata T., Ohashi K., Mizuno K., Narumiya S. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999, 285(5429):895-898.
8. Rath N., Olson M.F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 2012, 13(10):900-908.
9. Amano M., Fukata Y., Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp. Cell Res. 2000, 261(1):44-51.
10. Matsui T., Maeda M., Doi Y., Yonemura S., Amano M., Kaibuchi K., Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol. 1998, 140(3):647-657.
11. Nagumo H., Ikenoya M., Sakurada K., Furuya K., Ikuhara T., Hiraoka H., Sasaki Y. Rho-associated kinase phosphorylates MARCKS in human neuronal cells. Biochem. Biophys. Res. Commun. 2001, 280(3):605-609.
12. Olson M.F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 2008, 20(2):242-248.
13. Yao L., Romero M.J., Toque H.A., Yang G., Caldwell R.B., Caldwell R.W. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J. Cardiovasc. Dis. Res. 2010, 1(4):165-170.
14. Amano M., Nakayama M., Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010, 67(9):545-554.
15. Richardson B.T., Dibble C.F., Borikova A.L., Johnson G.L. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biol. Chem. 2013, 394(1):35-42.
16. Takayasu M., Suzuki Y., Shibuya M., Asano T., Kanamori M., Okada T., Kageyama N., Hidaka H. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J. Neurosurg. 1986, 65(1):80-85.
17. Suzuki Y., Yamamoto M., Wada H., Ito M., Nakano T., Sasaki Y., Narumiya S., Shiku H., Nishikawa M. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 1999, 93(10):3408-3417.
18. Suzuki Y., Shibuya M., Satoh S., Sugiyama H., Seto M., Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol. Med. Chir. (Tokyo) 2008, 48(6):241-247. discussion 7-8.
19. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002, 105(13):1545-1547.
20. Velat G.J., Kimball M.M., Mocco J.D., Hoh B.L. Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg. 2011, 76(5):446-454.
21. Kojonazarov B., Myrzaakhmatova A., Sooronbaev T., Ishizaki T., Aldashev A. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur. Respir. J. 2012, 39(2):496-498.
22. Fava A., Wung P.K., Wigley F.M., Hummers L.K., Daya N.R., Ghazarian S.R., Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res. (Hoboken) 2012, 64(6):925-929.
23. Yang X., Di J., Zhang Y., Zhang S., Lu J., Liu J., Shi W. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed. Pharmacother. 2012, 66(3):221-227.
24. Nakabayashi H., Shimizu K. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci. 2011, 102(2):393-399.
25. Deng L., Li G., Li R., Liu Q., He Q., Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol. Ther. 2010, 9(11):875-884.
26. Ogata S., Morishige K., Sawada K., Hashimoto K., Mabuchi S., Kawase C., Ooyagi C., Sakata M., Kimura T. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int. J. Gynecol. Cancer 2009, 19(9):1473-1480.
27. Ying H., Biroc S.L., Li W.W., Alicke B., Xuan J.A., Pagila R., Ohashi Y., Okada T., Kamata Y., Dinter H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther. 2006, 5(9):2158-2164.
28. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371(Pt 1):199-204.
29. Anastassiadis T., Deacon S.W., Devarajan K., Ma H., Peterson J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29(11):1039-1045.
30. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389(6654):990-994.
31. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5(2):221-225.
32. Sahai E., Ishizaki T., Narumiya S., Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr. Biol. 1999, 9(3):136-145.
33. Vigil D., Kim T.Y., Plachco A., Garton A.J., Castaldo L., Pachter J.A., Dong H., Chen X., Tokar B., Campbell S.L., Der C.J. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012, 72(20):5338-5347.
34. Schroter T., Griffin E., Weiser A., Feng Y., LoGrasso P. Detection of myosin light chain phosphorylation - a cell-based assay for screening Rho-kinase inhibitors. Biochem. Biophys. Res. Commun. 2008, 374(2):356-360.
35. Garton A.J., Castaldo L., Pachter J.A. Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases. Methods Enzymol. 2008, 439:491-500.
36. Muranyi A., MacDonald J.A., Deng J.T., Wilson D.P., Haystead T.A., Walsh M.P., Erdodi F., Kiss E., Wu Y., Hartshorne D.J. Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase. Biochem. J. 2002, 366(Pt 1):211-216.
37. Yuan B.Z., Jefferson A.M., Baldwin K.T., Thorgeirsson S.S., Popescu N.C., Reynolds S.H. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23(7):1405-1411.
38. Healy K.D., Hodgson L., Kim T.Y., Shutes A., Maddileti S., Juliano R.L., Hahn K.M., Harden T.K., Bang Y.J., Der C.J. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol. Carcinog. 2008, 47(5):326-337.
39. Yin Y., Lin L., Ruiz C., Cameron M.D., Pocas J., Grant W., Schroter T., Chen W., Duckett D., Schurer S., Lograsso P., Feng Y. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors. Bioorg. Med. Chem. Lett. 2009, 19(23):6686-6690.
40. Sessions E.H., Chowdhury S., Yin Y., Pocas J.R., Grant W., Schroter T., Lin L., Ruiz C., Cameron M.D., LoGrasso P., Bannister T.D., Feng Y. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II). Bioorg. Med. Chem. Lett. 2011, 21(23):7113-7118.
41. Kast R., Schirok H., Figueroa-Perez S., Mittendorf J., Gnoth M.J., Apeler H., Lenz J., Franz J.K., Knorr A., Hutter J., Lobell M., Zimmermann K., Munter K., Augstein K.H., Ehmke H., Stasch J.P. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br. J. Pharmacol. 2007, 152(7):1070-1080.
42. Fang X., Yin Y., Chen Y.T., Yao L., Wang B., Cameron M.D., Lin L., Khan S., Ruiz C., Schroter T., Grant W., Weiser A., Pocas J., Pachori A., Schurer S., Lograsso P., Feng Y. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J. Med. Chem. 2010, 53(15):5727-5737.
43. Doe C., Bentley R., Behm D.J., Lafferty R., Stavenger R., Jung D., Bamford M., Panchal T., Grygielko E., Wright L.L., Smith G.K., Chen Z., Webb C., Khandekar S., Yi T., Kirkpatrick R., Dul E., Jolivette L., Marino J.P., Willette R., Lee D., Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 2007, 320(1):89-98.
44. Hahmann C., Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 2010, 67(2):171-177.
45. Surma M., Wei L., Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 2011, 7(5):657-671.
46. Dong M., Yan B.P., Liao J.K., Lam Y.Y., Yip G.W., Yu C.M. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov. Today 2010, 15(15-16):622-629.
47. McKinsey T.A., Kass D.A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 2007, 6(8):617-635.
48. Lai A., Frishman W.H. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol. Rev. 2005, 13(6):285-292.
49. Doggrell S.A. Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opin. Investig. Drugs 2005, 14(9):1157-1159.
50. Hu E., Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin. Ther. Targets 2005, 9(4):715-736.
51. Yoneda A., Multhaupt H.A., Couchman J.R. The Rho kinases I and II regulate different aspects of myosin II activity. J. Cell Biol. 2005, 170(3):443-453.
52. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9(7):1956-1967.
53. Vega F.M., Fruhwirth G., Ng T., Ridley A.J. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J. Cell Biol. 2011, 193(4):655-665.
54. Li R., Martin M.P., Liu Y., Wang B., Patel R.A., Zhu J.Y., Sun N., Pireddu R., Lawrence N.J., Li J., Haura E.B., Sung S.S., Guida W.C., Schonbrunn E., Sebti S.M. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J. Med. Chem. 2012, 55(5):2474-2478.
55. Boerma M., Fu Q., Wang J., Loose D.S., Bartolozzi A., Ellis J.L., McGonigle S., Paradise E., Sweetnam P., Fink L.M., Vozenin-Brotons M.C., Hauer-Jensen M. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis 2008, 19(7):709-718.
56. Bustelo X.R., Sauzeau V., Berenjeno I.M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007, 29(4):356-370.
57. Pireddu R., Forinash K.D., Sun N.N., Martin M.P., Sung S.S., Alexander B., Zhu J.Y., Guida W.C., Schonbrunn E., Sebti S.M., Lawrence N.J. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). MedChemComm 2012, 3(6):699-709.
58. Chowdhury S., Sessions E.H., Pocas J.R., Grant W., Schroter T., Lin L., Ruiz C., Cameron M.D., Schurer S., LoGrasso P., Bannister T.D., Feng Y. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). Bioorg. Med. Chem. Lett. 2011, 21(23):7107-7112.
59. Sasaki Y., Suzuki M., Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 2002, 93(2-3):225-232.
60. Sessions E.H., Smolinski M., Wang B., Frackowiak B., Chowdhury S., Yin Y., Chen Y.T., Ruiz C., Lin L., Pocas J., Schroter T., Cameron M.D., LoGrasso P., Feng Y., Bannister T.D. The development of benzimidazoles as selective rho kinase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20(6):1939-1943.
61. Stavenger R.A., Cui H., Dowdell S.E., Franz R.G., Gaitanopoulos D.E., Goodman K.B., Hilfiker M.A., Ivy R.L., Leber J.D., Marino J.P., Oh H.J., Viet A.Q., Xu W., Ye G., Zhang D., Zhao Y., Jolivette L.J., Head M.S., Semus S.F., Elkins P.A., Kirkpatrick R.B., Dul E., Khandekar S.S., Yi T., Jung D.K., Wright L.L., Smith G.K., Behm D.J., Doe C.P., Bentley R., Chen Z.X., Hu E., Lee D. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J. Med. Chem. 2007, 50(1):2-5.
62. Chen Y.T., Bannister T.D., Weiser A., Griffin E., Lin L., Ruiz C., Cameron M.D., Schurer S., Duckett D., Schroter T., LoGrasso P., Feng Y. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(24):6406-6409.
63. Fang X., Chen Y.T., Sessions E.H., Chowdhury S., Vojkovsky T., Yin Y., Pocas J.R., Grant W., Schroter T., Lin L., Ruiz C., Cameron M.D., LoGrasso P., Bannister T.D., Feng Y. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors. Bioorg. Med. Chem. Lett. 2011, 21(6):1844-1848.
64. Sessions E.H., Yin Y., Bannister T.D., Weiser A., Griffin E., Pocas J., Cameron M.D., Ruiz C., Lin L., Schurer S.C., Schroter T., LoGrasso P., Feng Y. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg. Med. Chem. Lett. 2008, 18(24):6390-6393.
65. Feng Y., Yin Y., Weiser A., Griffin E., Cameron M.D., Lin L., Ruiz C., Schurer S.C., Inoue T., Rao P.V., Schroter T., Lograsso P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J. Med. Chem. 2008, 51(21):6642-6645.
66. Iwakubo M., Takami A., Okada Y., Kawata T., Tagami Y., Ohashi H., Sato M., Sugiyama T., Fukushima K., Iijima H. Design and synthesis of Rho kinase inhibitors (II). Bioorg. Med. Chem. 2007, 15(1):350-364.
67. Tokushige H., Inatani M., Nemoto S., Sakaki H., Katayama K., Uehata M., Tanihara H. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest. Ophthalmol. Vis. Sci. 2007, 48(7):3216-3222.
68. Sehon C.A., Wang G.Z., Viet A.Q., Goodman K.B., Dowdell S.E., Elkins P.A., Semus S.F., Evans C., Jolivette L.J., Kirkpatrick R.B., Dul E., Khandekar S.S., Yi T., Wright L.L., Smith G.K., Behm D.J., Bentley R., Doe C.P., Hu E., Lee D. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J. Med. Chem. 2008, 51(21):6631-6634.
69. Patel R.A., Forinash K.D., Pireddu R., Sun Y., Sun N., Martin M.P., Schonbrunn E., Lawrence N.J., Sebti S.M. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012, 72(19):5025-5034.
70. Rajagopalan L.E., Davies M.S., Kahn L.E., Kornmeier C.M., Shimada H., Steiner T.A., Zweifel B.S., Wendling J.M., Payne M.A., Loeffler R.F., Case B.L., Norton M.B., Parikh M.D., Nemirovskiy O.V., Mourey R.J., Masferrer J.L., Misko T.P., Kolodziej S.A. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity. J. Pharmacol. Exp. Ther. 2010, 333(3):707-716.
71. Goodman K.B., Cui H., Dowdell S.E., Gaitanopoulos D.E., Ivy R.L., Sehon C.A., Stavenger R.A., Wang G.Z., Viet A.Q., Xu W., Ye G., Semus S.F., Evans C., Fries H.E., Jolivette L.J., Kirkpatrick R.B., Dul E., Khandekar S.S., Yi T., Jung D.K., Wright L.L., Smith G.K., Behm D.J., Bentley R., Doe C.P., Hu E., Lee D. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J. Med. Chem. 2007, 50(1):6-9.
72. Iwakubo M., Takami A., Okada Y., Kawata T., Tagami Y., Sato M., Sugiyama T., Fukushima K., Taya S., Amano M., Kaibuchi K., Iijima H. Design and synthesis of rho kinase inhibitors (III). Bioorg. Med. Chem. 2007, 15(2):1022-1033.
73. Lohn M., Plettenburg O., Ivashchenko Y., Kannt A., Hofmeister A., Kadereit D., Schaefer M., Linz W., Kohlmann M., Herbert J.M., Janiak P., O'Connor S.E., Ruetten H. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009, 54(3):676-683.
74. Patel R.A., Liu Y., Wang B., Li R., Sebti S.M. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 2013.
75. Asano T., Suzuki T., Tsuchiya M., Satoh S., Ikegaki I., Shibuya M., Suzuki Y., Hidaka H. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br. J. Pharmacol. 1989, 98(4):1091-1100.
76. Yarrow J.C., Totsukawa G., Charras G.T., Mitchison T.J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 2005, 12(3):385-395.